Integrin beta-6 (ITGB6)

Class

Integrin beta-6-directed antibody-drug conjugate (MMAE/microtubule inhibitor payload)

Pathway

Antibody-mediated MMAE delivery inhibits microtubule polymerization, causing G2/M arrest and apoptosis

Integrin beta-6 (ITGB6) is a subunit that pairs with integrin alpha-v to form the cell-surface receptor αvβ6. This integrin is normally expressed at low levels, mainly on epithelial cells during tissue repair, where it helps cells adhere to the extracellular matrix and activates latent transforming growth factor-beta, a protein involved in tissue remodeling. In many epithelial-derived tumors, αvβ6 is markedly overexpressed on the cell surface while remaining largely absent from healthy adult tissue, making it an attractive marker for tumor-selective drug delivery. Rather than blocking a growth-promoting signal directly, therapeutic strategies exploit ITGB6 as a docking point: an antibody engineered to recognize this integrin is chemically linked to a cytotoxic payload, forming an antibody-drug conjugate (ADC). Once the antibody binds the receptor on the tumor cell surface, the complex is internalized, and enzymatic processing inside the cell releases the attached drug, which disrupts microtubule function and halts cell division, ultimately triggering cell death. This targeting approach is relevant across solid tumors that display high, relatively restricted ITGB6 expression, offering a way to concentrate cytotoxic activity within malignant epithelial tissue while sparing much of the surrounding normal tissue that lacks the receptor.